SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-24-169188
Filing Date
2024-06-26
Accepted
2024-06-26 17:12:13
Documents
17

Document Format Files

Seq Description Document Type Size
1 424B5 d849125d424b5.htm 424B5 638380
2 GRAPHIC g849125g00o78.jpg GRAPHIC 66244
3 GRAPHIC g849125g03u81.jpg GRAPHIC 73873
4 GRAPHIC g849125g07f17.jpg GRAPHIC 37651
5 GRAPHIC g849125g10w21.jpg GRAPHIC 38949
6 GRAPHIC g849125g12v58.jpg GRAPHIC 64330
7 GRAPHIC g849125g19e51.jpg GRAPHIC 39465
8 GRAPHIC g849125g24e85.jpg GRAPHIC 133632
9 GRAPHIC g849125g26m06.jpg GRAPHIC 38350
10 GRAPHIC g849125g29g39.jpg GRAPHIC 60800
11 GRAPHIC g849125g34o62.jpg GRAPHIC 78142
12 GRAPHIC g849125g51j09.jpg GRAPHIC 39151
13 GRAPHIC g849125g79j42.jpg GRAPHIC 69770
14 GRAPHIC g849125g88y18.jpg GRAPHIC 61785
15 GRAPHIC g849125g92s54.jpg GRAPHIC 50576
16 GRAPHIC g849125g98o95.jpg GRAPHIC 35357
17 GRAPHIC g849125g98y29.jpg GRAPHIC 58915
  Complete submission text file 0001193125-24-169188.txt   1940474
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-260069 | Film No.: 241074479
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)